VEGF pathway genetic variants as biomarkers of treatment outcome with bevacizumab: an analysis of data from the AViTA and AVOREN randomised trials — Diether Lambrechts (2012) | RDL Network
Sanne de Haas, Paul Delmar, Aruna T. Bansal, Matthieu Moisse, David Miles, Natasha B. Leighl, Bernard Escudier, Eric Van Cutsem, Peter Carmeliet, Stefan Scherer, Céline Pallaud, Diether Lambrechts
Daniel I. Swerdlow, David Preiss, Karoline Kuchenbaecker, Michael V. Holmes, Jorgen Engmann, Tina Shah, Reecha Sofat, Stefan Stender, P. Johnson, Robert A. Scott, Maarten Leusink, Niek Verweij, Stephen J. Sharp, Yiran Guo, Claudia Giambartolomei, Christina Lee Chung, Anne Peasey, Antoinette Amuzu, KaWah Li, Jutta Palmen, Philip Howard, Jackie A. Cooper, Fotios Drenos, Gordon Lowe,
Johannes Grand, Kristina Miger, Ahmad Sajadieh, Lars Køber, Christian Torp‐Pedersen, Georg Ertl, José López‐Sendón, Aldo Maggioni, John R. Teerlink, Naoki Sato, Claudio Gimpelewicz, Marco Metra, Thomas Holbro, Olav Wendelboe Nielsen
Shu‐Chun Chuang, Anouar Fanidi, Per Magne Ueland, Caroline L. Relton, Øivind Midttun, Dan Joseph Stein, Marc J. Gunter, Michael J. Seckl, Ruth C. Travis, Nicholas J. Wareham, Antonia Trichopoulou, Παγώνα Λάγιου, Dimitrios Trichopoulos, Petra H. Peeters, H. Bas Bueno-de-Mesquita, Heiner Boeing, Angelika Wientzek, Tilman Küehn, Rudolf Kaaks, Rosario Tumino, Claudia Agnoli, Domenico Palli, Alessio Naccarati,
Discussion(0)
No comments yet. Be the first to comment.